Abstract
Therapy with DNA topoisomerase II inhibitors has been shown to result in an increased risk of acute myeloid leukemia (AML), often presenting balanced translocations to chromosome bands 11q23 and 21q22. Also other balanced aberrations, more rarely observed in therapy-related AML (t-AML), such as t(15;17) and inv(16) have been associated with these drugs. Recently we observed a case of chronic myeloid leukemia (CML) with t(9;22) after therapy of a germ cell tumor with etoposide, cisplatin and bleomycin. Based on this case and a review of chemotherapy-related leukemias with t(9;22) from the literature, we suggest a causal relationship between therapy with DNA topoisomerase II inhibitors and development of various types of leukemia carrying the Philadelphia chromosome.
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Pedersen-Bjergaard, J., Brøndum-Nielsen, K., Karle, H. et al. Chemotherapy-related – and late occurring – Philadelphia chromosome in AML, ALL and CML. Similar events related to treatment with DNA topoisomerase II inhibitors?. Leukemia 11, 1571–1574 (1997). https://doi.org/10.1038/sj.leu.2400769
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2400769
- Springer Nature Limited
Keywords
This article is cited by
-
Chronic myeloid leukemia following the treatment of rectal adenocarcinoma
Medical Oncology (2008)
-
A novel translocation t(3;21)(p21;q22) in acute myelogenous leukemia preceding a late-appearing Philadelphia chromosome
Leukemia (2006)
-
Common chromatin structures at breakpoint cluster regions may lead to chromosomal translocations found in chronic and acute leukemias
Human Genetics (2006)
-
Secondary Philadelphia chromosome after non-myeloablative peripheral blood stem cell transplantation for a myelodysplastic syndrome in transformation
Bone Marrow Transplantation (2004)